The company was founded by biotechnology investors and financial executives who have invested in biotechnology startups and been involved in many due diligence practices prior to investing.
Our founder recognized the importance of certain recent major scientific breakthroughs in AI machine learning in predicting protein folding that can identify failures earlier and provide data for more efficient allocation of investment capital. These advantages are now available to our clients.
AI and machine learning in biotechnology has the power to filter and extract value from volumes of raw digital information housed in the world’s data banks. These technologies can sort through millions of data points in seconds and deliver complete data coverage which individual scientific consultants regardless of title or position can ever do. Further when coupled with any one of 60 “docking software” programs this process can be extremely predictive of the success or failure of an initial hypothesis or target interaction.